IDEAYA Biosciences to Showcase Pancreatic Cancer Pipeline in London R&D Day
Event summary
- IDEAYA Biosciences will host an Investor R&D Day in London on November 16, 2026, focusing on MTAP/CDKN2A and KRAS development strategies in pancreatic cancer.
- The event will feature new preclinical data and combination strategies to address tumor heterogeneity and adaptive plasticity.
- IDEAYA's leadership will participate in four investor conferences in September 2026, including Wells Fargo, Cantor Fitzgerald, Citi, and Morgan Stanley.
- Dr. Frank McCormick of UCSF will participate in the London R&D Day.
- Live and archived webcasts of all events will be available on IDEAYA's investor relations website.
The big picture
IDEAYA's focus on precision oncology aligns with the industry's shift toward targeted therapies for genetically defined cancer subtypes. The company's emphasis on synthetic lethality and ADCs positions it within a growing segment of the oncology market seeking more selective treatments. The upcoming investor events will be critical in assessing whether IDEAYA can differentiate itself among competitors pursuing similar precision medicine approaches.
What we're watching
- Pipeline Progress
- How IDEAYA's preclinical data on MTAP/CDKN2A and KRAS strategies will position it in the competitive pancreatic cancer treatment landscape.
- Combination Strategies
- Whether IDEAYA's approach to addressing tumor heterogeneity through rational combination therapies will gain investor traction.
- Investor Engagement
- The pace at which IDEAYA can convert conference presentations into tangible partnerships or funding opportunities.
Related topics